Senzagen
  • Home
  • Services
    • At a glance
      • Testing with us
      • Who we work with
      • GLP
    • GARD: Skin and Respiratory Sensitization Testing
      • GARDskin: OECD TG 442E
      • GARDpotency: OECD TGP 4.106
      • GARDskin Medical Device: ISO 10993-10
      • GARDskin Dose-Response
      • GARDair
      • “Difficult-to-test” samples
    • Regulatory Toxicity Testing
      • Skin corrosion: OECD TG 431
      • Skin irritation: OECD TG 439
      • Skin sensitization: OECD TG 442C, 442D, 442E
      • Skin absorption: OECD TG 428
      • Eye irritation: OECD TG 492, 492B
      • Phototoxicity: OECD TG 432, 498
      • Genotoxicity: OECD TG 471, 487
      • Full list of regulatory tests
    • Biological Evaluation of Medical Devices
      • Overview
      • In vitro biocompatibility testing
        • Cytotoxicity: ISO 10993-5
        • Irritation: ISO 10993-23
        • Skin sensitization: ISO 10993-10
      • Substance-based Medical Devices
        • Mode of action
        • Penetration, distribution and absorption
    • Toxicology Advisory
      • Areas of expertise
      • The team
      • Medical Devices
      • Cosmetics
      • Chemicals
      • Pharmaceuticals
  • Science
    • GARD Technology
    • Science Behind
    • Scientific Publications
    • Posters
    • Webinars
  • Company
    • About Us
    • Sustainability
    • Career
    • Partners
  • Investors
    • SenzaGen at a Glance
    • Financial Reports
    • Press Releases
    • The Share
    • Analyst Coverage
    • Presentations
    • Corporate Governance
      • Management
      • Board of Directors
      • Auditor
      • Nomination Committee
      • Annual General Meeting
    • Calendar
    • Prospekt / Emission
  • News and Events
    • Press Releases
    • News Posts
    • Event Calendar
  • Contact
  • Get a quote
  • Search
  • Menu Menu

SenzaGen’s Newsletter Q1 2021

7 April, 2021

Click image to read the newsletter.

Share this entry
  • Share on Facebook
  • Share on X
  • Share on X
  • Share on WhatsApp
  • Share on LinkedIn
  • Share on Vk
  • Share on Reddit
  • Share by Mail
https://senzagen.com/wp-content/uploads/2020/07/News.png 133 146 Tina Dackemark Lawesson https://senzagen.com/wp-content/uploads/2017/01/LoggaSquare_RGB_liten_HF.png Tina Dackemark Lawesson2021-04-07 14:36:282021-12-08 16:42:57SenzaGen’s Newsletter Q1 2021

Quick Links

Contact
Privacy Policy (En)
Privacy Policy (Sv)
General Terms and Conditions

Pages

  • Home
  • Services
  • Investors
  • Contact
  • News and Events

Follow Us

SUBSCRIBE TO PRESS RELEASES

SOT 2021 Recap: Spotlight on Dose-Response and the MDCPSS Best Overall Abstract...GARDskin and GARDpotency: a proof of concept study to investigate the applicability...
Scroll to top

Subscribe


Prenumerera